Summary
Extremely limited human data; doses above 140 mg strongly discouraged. Fatal case reported at ~500 mg combined with MDAI (blood concentration 6.45 mg/L). Acts as monoamine releasing agent with 5-HT2A/5-HT2B agonist properties; chronic use may risk valvular heart disease via 5-HT2B activation. Described as less stimulating than MDMA with predominantly serotonergic effects. Always test substance purity; reagents produce MDMA-like reactions.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 50-60mg | 60-100mg | 100-150mg | 150mg+ |
| Insufflated | 30-40mg | 40-60mg | 60-100mg | 100mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Oral | 30-60 min | 30-60 min | 2-3 hrs | 1-2 hrs | 6-12 hrs |
| Insufflated | 5-10 min | 15-30 min | 2-3 hrs | 1-2 hrs | 6-12 hrs |
Tolerance
Build-up
develops rapidly after a single use
Reset
7–14 days for baseline
Effects
Positive
- Stimulation
- Increased energy/alertness
Negative
- Pupil dilation
- Teeth grinding
- Temperature regulation suppression
- Increased heart rate
- Weight loss
- Sweating
- Difficulty urinating
- Decreased need for sleep
- Decreased appetite
- Distrubed sleep patterns
- Bruxia
Positive
- Cognitive euphoria
- Empathy, affection, and sociability enhancement
- Euphoria
- Increased sociability
- Mood lift
Negative
- Anxiety
- Agressiveness
- Excessive talking
- Moodiness
- Time distortion
Positive
- Increased music appreciation
- Tactile enhancement
- Colour enhancement
- Bodily control enhancement
- Increased libido
- Tracers
Negative
- Increase sexuality
- Visual and audiotory hallucinations itchiness
- Auditory hallucination
- Auditory distortion